This story has been updated from a previous version to include information about Devyser's fourth-quarter and full-year financial results.

本文已根据德维舍公司第四季度及全年财务结果的信息，对早前版本进行了更新。

NEW YORK – Swedish molecular diagnostics company Devyser Diagnostics said on Wednesday that it has agreed to acquire CyberGene, a diagnostics firm that specializes in aneuploidy and male infertility testing, for SEK12.2 million ($1.4 million) in newly issued Devyser shares. Both companies are based in the greater Stockholm area..

纽约——瑞典分子诊断公司Devyser Diagnostics周三表示，已同意以1220万瑞典克朗（140万美元）的价格收购专门从事非整倍体和男性不育检测的诊断公司CyberGene，支付方式为新发行的Devyser股票。两家公司均位于大斯德哥尔摩地区。

'The transaction strengthens our product offering within aneuploidy and male infertility, while at the same time improving our gross margins,' Devyser CEO Jan Wahlström said in a statement.

“该交易加强了我们在非整倍体和男性不育领域的产品供应，同时提高了我们的毛利率，”Devyser首席执行官Jan Wahlström在一份声明中表示。

The acquisition is expected to close by April 1. It is contingent upon necessary clearances, approvals, decisions, and other actions from the Inspectorate of Strategic Products under the Swedish Screening of Foreign Direct Investments Act, Devyser said.

预计收购将在4月1日前完成。Devyser表示，该交易取决于瑞典外国直接投资审查法下战略产品监察局的必要批准、决定和其他行动。

According to its website, CyberGene, based in Solna, is part of the Level Bio group, a public Swedish company. It offers quantitative fluorescence PCR (QF-PCR) prenatal tests for aneuploidy detection and Y-chromosome microdeletion tests for male infertility.

根据其网站信息，位于索尔纳的赛博基因（CyberGene）隶属于瑞典上市公司Level Bio集团。该公司提供用于非整倍体检测的定量荧光PCR（QF-PCR）产前测试，以及用于男性不育的Y染色体微缺失测试。

On Thursday, Devyser said that for the fourth quarter ended Dec. 31, it recorded an operating profit of SEK 18.0 million, or SEK 0.82 per share, compared to a loss of SEK 3.7 million in the same quarter a year ago. Likewise, for full-year 2025 the company's profit amounted to SEK 10.1 million, or a loss per share of SEK 0.51, compared to a loss of 62.3 million in 2024.

周四，Devyser 表示，截至 12 月 31 日的第四季度，公司录得营业利润为 1800 万瑞典克朗，每股收益 0.82 瑞典克朗，而去年同期则亏损 370 万瑞典克朗。同样，2025 年全年公司的利润达到 1010 万瑞典克朗，每股亏损 0.51 瑞典克朗，而 2024 年亏损为 6230 万瑞典克朗。

The company noted that this is its first positive full-year operating result..

公司指出，这是其首个全年营业利润为正的成绩。

Devyser's Q4 net sales were SEK 72.0 million, up 12 percent from SEK 64.2 million a year ago. Its full-year sales increased 15 percent to SEK 250.5 million from SEK $216.9 million in 2024.

德维赛尔第四季度的净销售额为7200万瑞典克朗，较去年的6420万瑞典克朗增长了12%。其全年销售额从2024年的2.169亿瑞典克朗增长15%至2.505亿瑞典克朗。